Your browser doesn't support javascript.
loading
Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma.
Khan, Abdullah M; Dvorak, Kiatlyn; Zhao, Qiuhong; Bumma, Naresh; Cottini, Francesca; Devarakonda, Srinivas; Umyarova, Elvira; Sharma, Nidhi; Benson, Don; Rosko, Ashley.
Affiliation
  • Khan AM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210. Abdullah.Khan@osumc.edu.
  • Dvorak K; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Zhao Q; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Bumma N; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Cottini F; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Devarakonda S; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Umyarova E; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Sharma N; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Benson D; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
  • Rosko A; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Haematologica ; 108(12): 3477-3479, 2023 Dec 01.
Article in En | MEDLINE | ID: mdl-37439332
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2023 Type: Article